A5015015784- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Surgical Treatments
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Ferroptosis and cancer prognosis
- Economic and Financial Impacts of Cancer
- Colorectal and Anal Carcinomas
- Colorectal Cancer Screening and Detection
- Health Systems, Economic Evaluations, Quality of Life
- Virus-based gene therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lipoproteins and Cardiovascular Health
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Radiomics and Machine Learning in Medical Imaging
Peter MacCallum Cancer Centre
2019-2025
The University of Melbourne
2016-2025
University of Cambridge
2025
Tung Wah College
2025
Walter and Eliza Hall Institute of Medical Research
2015-2024
The Royal Melbourne Hospital
2012-2022
BC Cancer Agency
2016-2022
Western Health
2022
Pancreas Centre (Canada)
2017-2021
Vancouver General Hospital
2013-2020
Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common types through assessment of the levels circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, 1005 patients with nonmetastatic, clinically detected cancers ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive median 70% types. The sensitivities ranged from 69 98% for five (ovary, esophagus)...
Detection of circulating tumor DNA in patients with resected stage II colon cancer provides evidence residual disease.
In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker minimal residual disease, is powerful prognostic factor in nonmetastatic cancer (CRC). Serial analysis ctDNA CRLM could inform optimal use perioperative chemotherapy. Here, we performed validation study confirm impact observed previous discovery study.We prospectively...
Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer types and potential therapeutic implications. Although varying results reported other types, the efficacy of HER-family kinase inhibitor afatinib treatment NRG1 fusion-positive pancreatic ductal adenocarcinoma is not fully understood.Forty-seven patients with received comprehensive whole-genome transcriptome sequencing analysis. Two gene treatment, response measured by pretreatment posttreatment PET/CT...
Abstract Studies in multiple solid tumor types have demonstrated the prognostic significance of ctDNA analysis after curative intent surgery. A combined data across completed studies could further our understanding circulating DNA (ctDNA) as a marker and inform future trial design. We individual patient from three independent cohort nonmetastatic colorectal cancer (CRC). Plasma samples were collected 4 to 10 weeks Mutations assayed using massively parallel sequencing technique called...
Abstract Oncogenic KRAS mutations are absent in approximately 10% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and may represent a subgroup mPDAC therapeutic options beyond standard-of-care cytotoxic chemotherapy. While distinct gene fusions have been implicated wildtype mPDAC, information regarding other types remain limited, expression patterns associated not reported. Here, we leverage sequencing data from the PanGen trial to perform comprehensive characterization...
Thromboprophylaxis for individuals receiving systemic anticancer therapies has proven to be effective. Potential maximize benefits relies on improved risk-directed strategies, but existing risk models underperform in cohorts with lung and gastrointestinal cancers.
Vitamin D has been implicated as a protective agent against colorectal cancer. We hypothesized that functional start codon polymorphism in the vitamin receptor (VDR) influences risk of carcinoma. conducted case-control study nested within large cohort Singapore Chinese. VDR genotypes, determined by Fok I restriction endonuclease digestion PCR-amplified DNA, were performed on 217 cancer cases and 890 controls. found compared with individuals carrying FF genotype, those Ff genotype had 51%...
In Stage II colon cancer, multiple independent studies have shown that a dense intratumoural immune infiltrate (local inflammation) is associated with improved outcomes, while systemic inflammation, measured by various markers, has been poorer outcomes. However, previous not considered the interaction between local and nor they assessed type of inflammatory response compared standard clinicopathologic criteria. order to evaluate potential clinical utility markers in we examined inflammation...
Abstract Purpose: RNA-sequencing–based subtyping of pancreatic ductal adenocarcinoma (PDAC) has been reported by multiple research groups, each using different methodologies and patient cohorts. “Classical” “basal-like” PDAC subtypes are associated with survival differences, basal-like tumors worse prognosis. We amalgamated various tools to evaluate the potential such be reliable in clinical practice. Experimental Design: Sequencing data for 574 was obtained from prospective trials...
Pancreatic neuroendocrine tumors (PNETs) are a genomically and clinically heterogeneous group of pancreatic neoplasms often diagnosed with distant metastases. Recurrent somatic mutations, chromosomal aberrations, gene expression signatures in PNETs have been described, but the clinical significance these molecular changes is still poorly understood, outcomes PNET patients remain highly variable. To help identify factors that contribute to progression metastasis, as part an ongoing trial at...
Abstract Background The changing treatment landscape for metastatic colorectal cancer creates multiple potential strategies. An A ustralian‐centric database capturing comprehensive information across a range of locations would create valuable resource enabling important research questions to be addressed. Aims To establish collection consensus dataset and outcomes at public private hospitals ustralia. Methods electronic was developed by panel clinicians, capture an agreed patients with newly...
We report a case of early-onset pancreatic ductal adenocarcinoma in patient harboring biallelic MUTYH germline mutations, whose tumor featured somatic mutational signatures consistent with defective -mediated base excision repair and the associated driver KRAS transversion mutation p.Gly12Cys. Analysis an additional 730 advanced cancer cases ( N = 731) was undertaken to determine whether were also present tumors from heterozygote carriers or if instead only seen those loss function....
70 Background: BRAFV600E-mutant metastatic colorectal cancer (mCRC) represents a unique molecular subset with poor prognosis and less responsiveness to chemotherapy. The BEACON CRC study demonstrated that encorafenib plus cetuximab (EC) significantly improved overall survival (OS) compared FOLFIRI in BRAF-mutant mCRC as 2 nd or 3 rd line therapy. This combination was reimbursed Australia from January 2022. Methods: We analysed data the Australian TRACC clinical registry, encompassing...